Cover Image

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain. This study sought to evaluate its economic value in patients with myocardial infarction (MI) from the Chinese healthcare perspective.Methods: A st...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhe Liang (Author), Qi Chen (Author), Ruiqi Wei (Author), Chenyao Ma (Author), Xuehui Zhang (Author), Xue Chen (Author), Fang Fang (Author), Quanming Zhao (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility
by: S. K. Zyryanov, et al.
Published: (2018)

Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
by: T. O. Bessonova, et al.
Published: (2023)

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES
by: Gregory P. Geba, et al.
Published: (2024)

A Prediction Model Based on Systemic Immune-Inflammatory Index Combined with Other Predictors for Major Adverse Cardiovascular Events in Acute Myocardial Infarction Patients
by: Li X, et al.
Published: (2024)

Cost-effectiveness and cost-utility analysis of the use of clopidogrel and pantoprazole in comparison with clopidogrel and omeprazole for the secondary prevention of myocardial infarction in Iran
by: Mohammadreza Amirsadri, et al.
Published: (2021)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
by: Hye Duck Choi, et al.
Published: (2023)

Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway
by: Jing Liu, et al.
Published: (2021)

New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins
by: Jah Yeon Choi, et al.
Published: (2021)

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran
by: Mohammadreza Amirsadri, et al.
Published: (2017)

Ticagrelor Loading on ST-Elevation Myocardial Infarction: Interaction With Prodromal Angina on Infarct Size and Clinical Events
by: João Pedro Faria MD, et al.
Published: (2023)

The Clinical Efficaciency and the Cost-Effectiveness of Reperfusion Therapy in Myocardial Infarction
by: A. M. Nazarov, et al.
Published: (2015)

PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
by: Klaus G. Parhofer, et al.
Published: (2019)

SYNTAX score as predictor of adverse events in patients after acute myocardial infarction
by: Davidović Aleksandar, et al.
Published: (2021)

Going beyond the mean: economic benefits of myocardial infarction secondary prevention
by: Viktor von Wyl, et al.
Published: (2020)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
by: Obamiro Kehinde, et al.
Published: (2016)

Gender and secondary risk assessment following an ST-elevation myocardial infarction
by: Scruth E, et al.
Published: (2013)

Non-ST elevation myocardial infarction secondary to carbon monoxide intoxication
by: Danuta Jankowska, et al.
Published: (2017)

Predictors of recurrent cardiovascular events in patients with a single-vessel coronary artery disease after ST-segment elevation myocardial infarction
by: V. E. Oleynikov, et al.
Published: (2023)

Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs - an analysis of real-world data
by: Florian Kirsch, et al.
Published: (2020)

Myocardial Infarction
Published: (2019)

Pulse pressure and inferior wall ST‑segment elevation myocardial infarction: investigating mortality, hospital major cardiovascular events, and long‑term prognosis
by: Enayatollah Enayatollah Hashemi-Jokandan, et al.
Published: (2023)

Acute myocardial infarction-like event in a young patient with biventricular arrhythmogenic cardiomyopathy
by: Y. V. Stavtseva, et al.
Published: (2024)

SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES AMONG PATIENTS OF DIFFERENT AGE GROUPS WITH A HISTORY OF MYOCARDIAL INFARCTION BY THE EXAMPLE OF OUTPATIENT CARDIOLOGY INSTITUTION
by: S. B. Fitilev, et al.
Published: (2017)

Acute myocardial infarction in myocardial revascularization
by: Dr. Karel Morlans Hernández, et al.
Published: (2014)

Temporal trends in healthcare resource utilization and costs following acute myocardial infarction
by: Arthur Shiyovich, et al.
Published: (2020)

Comparative treatment costs for patients with acute myocardial infarction between Finland and Norway
by: Tor Iversen, et al.
Published: (2019)

Reproductive factors and risk of cardiovascular outcomes in women with ST-elevation myocardial infarction
by: Sina Rouhani, et al.
Published: (2024)

SOTAGLIFLOZIN SIGNIFICANTLY REDUCES CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN THE SCORED TRIAL
by: Deepak L. Bhatt, et al.
Published: (2023)

Economic Burden of Myocardial Infarction Combined With Dyslipidemia
by: Pingyu Chen, et al.
Published: (2021)

Acute Myocardial Infarction During Pregnancy
by: Yu-Ching Chen, et al.
Published: (2009)

Perioperative myocardial infarction
by: Larry Nichols
Published: (2018)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
by: Farag M, et al.
Published: (2015)

CHANGE OF ARRHYTHMIC EVENTS IN ACUTE MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION AFTER PHARMACOINVASIVE REVASCULARIZATION
by: V. E. Oleynikov, et al.
Published: (2017)

What should be done in the event of simultaneous massive pulmonary embolism and myocardial infarction with ST elevation?
by: Recep Akgedik, et al.
Published: (2015)

NEW EVIDENCES OF POSSIBILITY OF OMEGA-3 ACIDS USE FOR MYOCARDIAL INFARCTION SECONDARY PREVENTION
by: A. I. Martinov, et al.
Published: (2016)

Expression alteration of serum exosomal circular RNAs in obstructive sleep apnea patients with acute myocardial infarction
by: Jie-feng Huang, et al.
Published: (2023)

An Efficient Predictive Model for Myocardial Infarction Using Cost-sensitive J48 Model
by: Atefeh DARAEI, et al.
Published: (2017)

LIPID CONTROL IN PATIENTS AFTER MYOCARDIAL INFARCTION - AN EFFECTIVE TOOL FOR MANAGING CARDIOVASCULAR RISKS
by: O. L. Barbarash, et al.
Published: (2017)

The Pharmacogenetics of Statin Therapy on Clinical Events: No Evidence that Genetic Variation Affects Statin Response on Myocardial Infarction
by: Stella Trompet, et al.
Published: (2022)